Insider trade

CFO received an award of 26K COLL shares

Traded Feb 10, 2026 · Filed Feb 12, 2026

Collegium Pharmaceutical, Inc.COLL

26K
Shares

Why it stands out

Compensation award — excluded from discretionary-purchase analysis.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Feb 10, 2026
Reporting period: Not applicable
Filed with the SEC: Feb 12, 2026

CFOGrant / award

Context

Classification

grant award

Code A — grant or award

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001862082-26-000002
Filed / recorded

Feb 12, 2026, 9:30 PM UTC

Added to OQRO

Oct 6, 2026, 10:35 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

COLLEGIUM PHARMACEUTICAL, INC

Issuer CIK

1267565

Ticker

COLL

Reporting person

Colleen Tupper

Relationship

Officer

Officer title

EVP & Chief Financial Officer

Security

Common Stock

Table

Non-derivative (Table I)

Transaction date

Feb 10, 2026

Transaction code

A

Shares / units

26,421

Price per share

$0.00

Acquired / disposed

Acquired (A)

Shares owned after

153,088

Ownership form

Direct

Amendment

No

Footnotes from the filing

Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2027, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.

Around the same time

David Dieter (EVP & General Counsel) sold ~$228K of Collegium Pharmaceutical, Inc.

Scheduled in advanceFiled 7mo ago

Scott Dreyer (EVP & Chief Commercial Officer) sold ~$1.87M of Collegium Pharmaceutical, Inc.

Scheduled in advanceFiled 7mo ago

Scott Dreyer (EVP & Chief Commercial Officer) sold ~$146K of Collegium Pharmaceutical, Inc.

Scheduled in advanceFiled 7mo ago